378 related articles for article (PubMed ID: 27439378)
1. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.
Buonsanti C; Balocchi C; Harfouche C; Corrente F; Galli Stampino L; Mancini F; Tontini M; Malyala P; Bufali S; Baudner B; De Gregorio E; Valiante NM; O'Hagan DT; Rappuoli R; D'Oro U
Sci Rep; 2016 Jul; 6():29063. PubMed ID: 27439378
[TBL] [Abstract][Full Text] [Related]
2. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
[TBL] [Abstract][Full Text] [Related]
3. Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease.
Adamo R; Nilo A; Harfouche C; Brogioni B; Pecetta S; Brogioni G; Balducci E; Pinto V; Filippini S; Mori E; Tontini M; Romano MR; Costantino P; Berti F
Glycoconj J; 2014 Dec; 31(9):637-47. PubMed ID: 25256065
[TBL] [Abstract][Full Text] [Related]
4. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
5. Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM
Beresford NJ; Martino A; Feavers IM; Corbel MJ; Bai X; Borrow R; Bolgiano B
Vaccine; 2017 Jun; 35(28):3598-3606. PubMed ID: 28408122
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine.
Gonzalez-Lopez A; Oostendorp J; Koernicke T; Fadini T; D'Oro U; Baker S; O'Hagan DT; Del Giudice G; Siena E; Finco O; Medini D
Clin Immunol; 2019 Dec; 209():108275. PubMed ID: 31669193
[TBL] [Abstract][Full Text] [Related]
7. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.
Baraldo K; Mori E; Bartoloni A; Norelli F; Grandi G; Rappuoli R; Finco O; Del Giudice G
Infect Immun; 2005 Sep; 73(9):5835-41. PubMed ID: 16113302
[TBL] [Abstract][Full Text] [Related]
8. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
9. Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.
Siena E; Schiavetti F; Borgogni E; Taccone M; Faenzi E; Brazzoli M; Aprea S; Bardelli M; Volpini G; Buricchi F; Sammicheli C; Tavarini S; Bechtold V; Blohmke CJ; Cardamone D; De Intinis C; Gonzalez-Lopez A; O'Hagan DT; Nuti S; Seidl C; Didierlaurent AM; Bertholet S; D'Oro U; Medini D; Finco O
Vaccine; 2023 Jan; 41(3):724-734. PubMed ID: 36564274
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
11. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
[TBL] [Abstract][Full Text] [Related]
12. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
[TBL] [Abstract][Full Text] [Related]
13. Immune responses of a meningococcal A + W outer membrane vesicle (OMV) vaccine with and without aluminium hydroxide adjuvant in two different mouse strains.
Tunheim G; Arnemo M; Naess LM; Norheim G; Garcia L; Cardoso D; Mandiarote A; Gonzalez D; Sinnadurai K; Fjeldheim ÅK; Bolstad K; Rosenqvist E
APMIS; 2016 Nov; 124(11):996-1003. PubMed ID: 27651089
[TBL] [Abstract][Full Text] [Related]
14. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine.
Granoff DM; McHugh YE; Raff HV; Mokatrin AS; Van Nest GA
Infect Immun; 1997 May; 65(5):1710-5. PubMed ID: 9125551
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
[TBL] [Abstract][Full Text] [Related]
16. Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node.
Vo HTM; Baudner BC; Sammicheli S; Iannacone M; D'Oro U; Piccioli D
Front Immunol; 2018; 9():641. PubMed ID: 29686670
[TBL] [Abstract][Full Text] [Related]
17. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
[TBL] [Abstract][Full Text] [Related]
18. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
19. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants.
Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ
Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
